Literature DB >> 3580350

Is irradiation a justifiable treatment of choroidal melanoma? Analysis of published results.

W A Manschot, R Van Strik.   

Abstract

Analysis of the literature shows that dissemination of choroidal melanomas generally occurs after the 7 mm diameter stage, that doubling times of uveal melanomas vary from 30 to 365 days, and that death from metastases occurs 30-40 doubling times after dissemination. Tumour related death within three years after therapy is caused by pre-existing metastases. Survival rates for less than four years after therapy are therefore irrelevant in evaluating the efficacy of therapeutic regimens. Considerably higher postirradiation than postenucleation death rates after a mean 10-year follow-up period have been reported, and this difference can be explained by a reported mean clinical tumour regression rate of 31% two years after irradiation and histopathological studies which revealed that 42 out of 43 irradiated melanomas contained viable tumour, while only 50% showed necrosis. The doubtful value of preserving vision does not justify the high risk of avoidable death from metastases in irradiated patients.

Entities:  

Mesh:

Year:  1987        PMID: 3580350      PMCID: PMC1041164          DOI: 10.1136/bjo.71.5.348

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  30 in total

1.  Complications of cobalt plaque therapy of choroidal malanomas.

Authors:  D H Char; L I Lonn; L W Margolis
Journal:  Am J Ophthalmol       Date:  1977-10       Impact factor: 5.258

2.  The natural history of uveal melanomas and its therapeutic consequences.

Authors:  W A Manschot
Journal:  Doc Ophthalmol       Date:  1980-12-15       Impact factor: 2.379

3.  The place of radiotherapy in the treatment of uveal melanoma.

Authors:  P A MacFaul
Journal:  Doc Ophthalmol       Date:  1980-12-15       Impact factor: 2.379

4.  Histology of small melanomas.

Authors:  D de Wolff-Rouendaal; J A Oosterhuis
Journal:  Doc Ophthalmol       Date:  1980-12-15       Impact factor: 2.379

5.  Survival rates after enucleation of eyes with malignant melanoma.

Authors:  D Seigel; M Myers; F Ferris; S C Steinhorn
Journal:  Am J Ophthalmol       Date:  1979-06       Impact factor: 5.258

Review 6.  Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells.

Authors:  L E Zimmerman; I W McLean; W D Foster
Journal:  Br J Ophthalmol       Date:  1978-06       Impact factor: 4.638

7.  Small choroidal melanomas. A long-term follow-up study.

Authors:  J V Thomas; W R Green; A E Maumenee
Journal:  Arch Ophthalmol       Date:  1979-05

8.  Choroidal melanoma. Enucleation or observation? A new approach.

Authors:  W A Manschot; H A van Peperzeel
Journal:  Arch Ophthalmol       Date:  1980-01

9.  Small melanomas of the choroid.

Authors:  C C Barr; J O Sipperley; D H Nicholson
Journal:  Arch Ophthalmol       Date:  1978-09

10.  Histopathological changes in malignant melanomas of the choroid after cobalt plaque therapy.

Authors:  P A MacFaul; G Morgan
Journal:  Br J Ophthalmol       Date:  1977-03       Impact factor: 4.638

View more
  10 in total

1.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

Review 2.  Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review.

Authors:  W A Manschot; R van Strik
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

Review 3.  Prognosis in ocular melanoma.

Authors:  J Hungerford
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

4.  Uveal melanoma management.

Authors:  D H Char; E S Gragoudas; T L Phillips
Journal:  Br J Ophthalmol       Date:  1989-06       Impact factor: 4.638

5.  Irradiation and choroidal melanoma.

Authors:  L E Zimmerman; I W McLean
Journal:  Br J Ophthalmol       Date:  1988-07       Impact factor: 4.638

6.  Mode of presentation and time to treatment of uveal melanoma in Finland.

Authors:  S Eskelin; T Kivelä
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

Review 7.  Does ocular treatment of uveal melanoma influence survival?

Authors:  B Damato
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

Review 8.  Is observation really appropriate for small choroidal melanomas.

Authors:  J J Augsburger
Journal:  Trans Am Ophthalmol Soc       Date:  1993

9.  Transvitreal retinochoroidal biopsy.

Authors:  E Scherfig; J U Prause; O A Jensen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

10.  Is Collaborative Ocular Melanoma Study (COMS) still relevant?

Authors:  Santosh G Honavar
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.